CU20200030A7 - PEPTIDE FOR THE TREATMENT OF INFECTIONS CAUSED BY CORONAVIRUS - Google Patents

PEPTIDE FOR THE TREATMENT OF INFECTIONS CAUSED BY CORONAVIRUS

Info

Publication number
CU20200030A7
CU20200030A7 CU2020000030A CU20200030A CU20200030A7 CU 20200030 A7 CU20200030 A7 CU 20200030A7 CU 2020000030 A CU2020000030 A CU 2020000030A CU 20200030 A CU20200030 A CU 20200030A CU 20200030 A7 CU20200030 A7 CU 20200030A7
Authority
CU
Cuba
Prior art keywords
treatment
peptide
infections caused
coronavirus
prevention
Prior art date
Application number
CU2020000030A
Other languages
Spanish (es)
Inventor
Menéndez Evelin Caballero
Ortega Celia Berta Fernández
Nieto Gerardo Enrique Guillén
Negrín Yasser Perea
Rodríguez Silvio Ernesto Perea
Sánchez Ailyn De La Caridad Ramón
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Priority to CU2020000030A priority Critical patent/CU20200030A7/en
Priority to PCT/CU2021/050004 priority patent/WO2021239165A2/en
Publication of CU20200030A7 publication Critical patent/CU20200030A7/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>Péptido para el tratamiento o la prevención de infecciones originadas por coronavirus que se caracteriza porque posee una secuencia de aminoácidos identificada como SEQ ID NO: 1 Composición farmacéutica para el tratamiento o la prevención de dichas infecciones que se caracteriza porque comprende el mencionado péptido. Combinación farmacéutica para el tratamiento de infecciones originadas por coronavirus que se caracteriza porque comprende una composición que comprende el péptido cuya secuencia de aminoácidos se identifica como SEQ ID NO: 1 y un medicamento antiviral. La invención también comprende el uso del péptido para la fabricación de un medicamento para el tratamiento o la prevención de infecciones originadas por coronavirus, y métodos de tratamiento con dicho péptido.</p><p>Peptide for the treatment or prevention of infections caused by coronavirus characterized in that it has an amino acid sequence identified as SEQ ID NO: 1 Pharmaceutical composition for the treatment or prevention of said infections characterized in that it comprises the aforementioned peptide . Pharmaceutical combination for the treatment of infections caused by coronavirus characterized in that it comprises a composition comprising the peptide whose amino acid sequence is identified as SEQ ID NO: 1 and an antiviral drug. The invention also includes the use of the peptide for the manufacture of a medicament for the treatment or prevention of infections caused by coronaviruses, and methods of treatment with said peptide.</p>

CU2020000030A 2020-05-27 2020-05-27 PEPTIDE FOR THE TREATMENT OF INFECTIONS CAUSED BY CORONAVIRUS CU20200030A7 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CU2020000030A CU20200030A7 (en) 2020-05-27 2020-05-27 PEPTIDE FOR THE TREATMENT OF INFECTIONS CAUSED BY CORONAVIRUS
PCT/CU2021/050004 WO2021239165A2 (en) 2020-05-27 2021-05-27 Peptide for treating coronavirus infections

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2020000030A CU20200030A7 (en) 2020-05-27 2020-05-27 PEPTIDE FOR THE TREATMENT OF INFECTIONS CAUSED BY CORONAVIRUS

Publications (1)

Publication Number Publication Date
CU20200030A7 true CU20200030A7 (en) 2022-01-13

Family

ID=77411507

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000030A CU20200030A7 (en) 2020-05-27 2020-05-27 PEPTIDE FOR THE TREATMENT OF INFECTIONS CAUSED BY CORONAVIRUS

Country Status (2)

Country Link
CU (1) CU20200030A7 (en)
WO (1) WO2021239165A2 (en)

Also Published As

Publication number Publication date
WO2021239165A2 (en) 2021-12-02
WO2021239165A3 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
ECSP21042554A (en) STABILIZED RSV PREFUSION F PROTEINS
ECSP21051833A (en) COMBINATION OF DEXTROMETORPHAN AND BUPROPION FOR THE TREATMENT OF DEPRESSION
MX2020009856A (en) RIMEGEPANT FOR CALCITONIN GENE-RELATED PEPTIDE (CGRP)-RELATED DISORDERS.
CO2020009625A2 (en) Fap inhibitor
CO2022018715A2 (en) 1&#39;-cyano nucleoside analogues and uses thereof
CR20220491A (en) ANTIVIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF
PE20241305A1 (en) AMYLIN ANALOGUES
UY37998A (en) ANTIVIRAL AGENTS AGAINST HEPATITIS B
AR068302A1 (en) PEPTIDES FOR VACCINES FOR CANCERS EXPRESSING ANTIGENS ASSOCIATED WITH TUMORS
CR20240363A (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS.
UY30535A1 (en) COMPOSITION UNDERSTANDING ANTIRRETROVIRAL PHARMACOS AND AT LEAST AN INSOLUBLE WATER POLYMER, PREPARATION PROCESS AND APPLICATIONS.
CO2021007648A2 (en) 3,3- Difluoroallylamines or salts thereof and pharmaceutical compositions comprising them
CY1113115T1 (en) Peptides - HIV Fusion Inhibitors with Enhanced Biological Properties
BR112021020883A2 (en) Solid forms of a glyt1 inhibitor
CL2019001746A1 (en) Aromatic carboxylic acid amides
CL2021002107A1 (en) Triamterene or nolatrexed for use in the treatment of phenylketonuria.
EA202090802A1 (en) PEPTIDE COMPOSITION FOR TREATMENT OF DAMAGE ASSOCIATED WITH EXCITING NEUROTOXICITY
CU20200030A7 (en) PEPTIDE FOR THE TREATMENT OF INFECTIONS CAUSED BY CORONAVIRUS
CO2022004572A2 (en) Treatment of type 2 diabetes mellitus
CL2022000990A1 (en) Combination of a cxcr7 antagonist with a s1p1 receptor modulator
AR123998A1 (en) CHIMERIC PROTEIN COMPRISING THE RECEPTOR-BINDING DOMAIN OF THE CORONAVIRUS SPIKE PROTEIN AND COMPOSITIONS COMPRISING THEM
MX2022005388A (en) PYRROLIDINE AND PIPERIDINE COMPOUNDS.
MX2022011475A (en) AZD1656 FOR USE IN THE TREATMENT OF PNEUMONITIS AND/OR MYOCARDITIS CAUSED BY A CORONAVIRUS.
BR112018010497A2 (en) synergistic combination of pyrrolidone carboxylic acid and / or its salts and hyaluronic acid and / or its salts for use in the treatment and / or prevention of mucosal dryness and irritation and related pharmaceutical formulations
MX2017013480A (en) PHARMACEUTICAL COMPOSITION TO TREAT AND / OR PREVENT CANCER.